Nature CommunicationsBiophysicsPeer-reviewed journal article
Cryo-EM led analysis of open and closed conformations of Chagas vaccine candidate TcPOP and its antibody response characterisation
Sagar BatraiD, Francisco OlmoiD, Timothy J. RaganiD, Merve KaplaniD, Valeria CalvaresiiD, Asger Meldgaard FrankiD, Claudia LanceyiD, Mahya AssadipapariiD, Cuifeng YingiD, Weston B. StruweiD, Emma L. HeskethiD, John M. KellyiD, Lea Klingenberg BarfodiD, Ivan CampeottoiD
Abstract
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, remains a significant global public health concern. Despite its profound health impact in both endemic and non-endemic areas, no vaccine is available, and the existing therapies are outdated, producing severe side effects. The 80kDa prolyl oligopeptidase of Trypanosoma cruzi (TcPOP) has been recently identified as a leading candidate for Chagas vaccine development. We report the first three-dimensional structure of TcPOP in open and closed conformation, at a global resolution of 3.8 and 3.6 [A] respectively, determined using single-particle cryo-electron microscopy. Multiple conformations were observed and further characterized using plasmonic optical tweezers and hydrogen-deuterium exchange mass spectrometry. To assess the immunogenic potential of TcPOP, we immunized mice and evaluated both polyclonal and monoclonal responses against the TcPOP antigen and its homologues. The results revealed invasion blocking properties of anti-TcPOP polyclonal response via parasite lysis and its cross-reactivity versus closely-related POPs but not with human homologues. We were also able to produce and characterise three monoclonal antibodies, one of which showed neutralising properties and inhibition of parasite invasion via non-lytic mechanism. Collectively, our findings provide critical structural and functional insights necessary to understand the immunogenicity of TcPOP for future Chagas vaccine development and diagnostic applications.
- Citations
- 2
- FWCI
- 1.14
- Field percentile
- top 27%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunity conferred by drug-cured experimental Trypanosoma cruzi infections is long-lasting and cross-strain protective
G. S. Mann, A. F. Francisco, … J. Kelly·bioRxiv·Aug 20, 2019
- A genome wide antigen-antibody screen identifies a yeast-based therapeutic vaccine candidate for Chagas disease
Mira Loock, Lissa Cruz‐Saavedra, … Igor dos Santos Cestari·bioRxiv·Jun 13, 2026
- A Trypanosoma cruzi Antigen and Epitope Atlas: deep characterization of antibody specificities in Chagas Disease patients across the Americas
A. D. Ricci, L. E. Bracco, … F. Aguero·bioRxiv·Aug 19, 2022
- Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy
Jorge Andrés Calderón-Quintal, Christian Florian Teh-Poot, … Julio Vladimir Cruz-Chan·npj VaccinesPeer-reviewed·Dec 18, 2025
- Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in BALB/c mice.
V. M. Dzul-Huchim, M. J. Ramirez-Sierra, … L. E. Villanueva Lizama·bioRxiv·Feb 16, 2022
- Structural Basis of Glycolytic Control in Trypanosoma cruzi: Insights from Enolase and PGI
Kenneth Austin, Vincent A Obakachi, … Graham Chakafana·bioRxiv·Jan 15, 2026